<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034276</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00141495</org_study_id>
    <nct_id>NCT05034276</nct_id>
  </id_info>
  <brief_title>Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder</brief_title>
  <official_title>Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BehaVR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 trial that aims to establish the safety of MORE-VR, as well as to collect&#xD;
      feasibility, usability, and engagement data, for patients receiving medications for opioid&#xD;
      use disorder (mOUD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, as indicated by adverse events and serious adverse events</measure>
    <time_frame>Baseline through week 8</time_frame>
    <description>Types and frequencies of adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engagement</measure>
    <time_frame>Baseline through week 8</time_frame>
    <description>Net Promoter Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State craving</measure>
    <time_frame>Baseline through week 8</time_frame>
    <description>0 to 10 numeric rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State positive affect</measure>
    <time_frame>Baseline through week 8</time_frame>
    <description>0 to 10 numeric rating scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Desire for Drugs</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Desires for Drugs Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Trait positive and negative affect</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Positive and Negative Affect Schedule</description>
  </other_outcome>
  <other_outcome>
    <measure>Coping self-efficacy</measure>
    <time_frame>Baseline, week 8</time_frame>
    <description>Drug Taking Confidence Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Cue-elicited heart rate</measure>
    <time_frame>Baseline through week 8</time_frame>
    <description>Heart rate during cue exposure minus baseline heart rate</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>MORE-VR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindfulness-Oriented Recovery Enhancement deployed over virtual reality.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MORE-VR</intervention_name>
    <description>Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.</description>
    <arm_group_label>MORE-VR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  DSM-5 opioid use disorder diagnosis&#xD;
&#xD;
          -  treated with medications for opioid use disorder (MOUD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mindfulness intervention experience (MBSR, MBRP)&#xD;
&#xD;
          -  Active psychosis or high risk of suicidality&#xD;
&#xD;
          -  Cognitive impairment (per self-report or report by clinician)&#xD;
&#xD;
          -  Unwilling or unable to remain in MOUD treatment for duration of study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Research assistant</last_name>
    <phone>385-200-8595</phone>
    <email>utahVRstudy@utah.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Eric Garland</investigator_full_name>
    <investigator_title>Distinguished Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

